FDA approves Keytruda plus chemotherapy for cervical cancer – Merck
Merck Inc., announced that the FDA has approved Keytruda (pembrolizumab) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent or metastatic cervical cancer whose tumors express PD-L1 (Combined Positive Score [CPS] at least 1) as determined by an FDA-approved test. The approval is based on the Phase III KEYNOTE-826 trial evaluating Keytruda plus […]
Recent Comments